The U.S. Food and Drug Administration has granted approval to Amgen's biosimilar version of Johnson & Johnson's Stelara for the treatment of various inflammatory diseases. However, the launch of Amgen's treatment is expected to be delayed until 2025 due to a legal settlement between the two companies.
-The U.S. Food and Drug Administration on Tuesday approved Amgen 's biosimilar version of Johnson & Johnson's blockbuster psoriasis treatment, Stelara , for multiple inflammatory diseases.
Despite the FDA approval, Amgen's treatment is expected to be launched in 2025 as part of a legal settlement between the two companies earlier this year to delay the entry of the therapy.Stelara, introduced in 2009, has been J&J's top-selling drug since 2019, with sales reaching $9.7 billion in 2022.
FDA Approval Amgen Biosimilar Johnson & Johnson Stelara Inflammatory Diseases Legal Settlement
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Amgen's Biosimilar Version of Stelara for Multiple Inflammatory DiseasesThe U.S. Food and Drug Administration has granted approval to Amgen for their biosimilar version of Johnson & Johnson's popular psoriasis treatment, Stelara, for the treatment of various inflammatory diseases.
Read more »
Amgen Beats Earnings Expectations and Expands into Obesity Drug SpaceAmgen reported better-than-expected third-quarter earnings and raised its revenue guidance for the full year. The company recently acquired Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also venturing into the obesity drug market and has completed enrollment for a phase 2 trial for the treatment of obesity.
Read more »
Amgen third-quarter sales rise 5%; profit up before chargeAmgen, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit...
Read more »
Amgen Reports 5% Rise in Q3 Product Sales After Horizon Therapeutics AcquisitionAmgen announces a 5% increase in third-quarter product sales, driven by double-digit volume growth but offset by lower prices. The company also raises its post-acquisition sales forecast and adjusted earnings outlook for 2023.
Read more »